All Title Author
Keywords Abstract

PLOS ONE  2013 

Reduced Susceptibility of Plasmodium falciparum to Artesunate in Southern Myanmar

DOI: 10.1371/journal.pone.0057689

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Plasmodium falciparum resistance to artemisinins, the first line treatment for malaria worldwide, has been reported in western Cambodia. Resistance is characterized by significantly delayed clearance of parasites following artemisinin treatment. Artemisinin resistance has not previously been reported in Myanmar, which has the highest falciparum malaria burden among Southeast Asian countries. Methods A non-randomized, single-arm, open-label clinical trial of artesunate monotherapy (4 mg/kg daily for seven days) was conducted in adults with acute blood-smear positive P. falciparum malaria in Kawthaung, southern Myanmar. Parasite density was measured every 12 hours until two consecutive negative smears were obtained. Participants were followed weekly at the study clinic for three additional weeks. Co-primary endpoints included parasite clearance time (the time required for complete clearance of initial parasitemia), parasite clearance half-life (the time required for parasitemia to decrease by 50% based on the linear portion of the parasite clearance slope), and detectable parasitemia 72 hours after commencement of artesunate treatment. Drug pharmacokinetics were measured to rule out delayed clearance due to suboptimal drug levels. Results The median (range) parasite clearance half-life and time were 4.8 (2.1–9.7) and 60 (24–96) hours, respectively. The frequency distributions of parasite clearance half-life and time were bimodal, with very slow parasite clearance characteristic of the slowest-clearing Cambodian parasites (half-life longer than 6.2 hours) in approximately 1/3 of infections. Fourteen of 52 participants (26.9%) had a measurable parasitemia 72 hours after initiating artesunate treatment. Parasite clearance was not associated with drug pharmacokinetics. Conclusions A subset of P. falciparum infections in southern Myanmar displayed markedly delayed clearance following artemisinin treatment, suggesting either emergence of artemisinin resistance in southern Myanmar or spread to this location from its site of origin in western Cambodia. Resistance containment efforts are underway in Myanmar. Trial Registration Australian New Zealand Clinical Trials Registry ACTRN12610000896077

References

[1]  Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, et al. (2008) Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359: 2619–2620.
[2]  Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455–467.
[3]  Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, et al. (2012) Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 12: 851–858.
[4]  World Health Organization (2011) Global plan for artemisinin resistance containment (GPARC). Available: http://www.who.int/malaria/publications/?atoz/artemisinin_resistance_containment_?2011.pdf. Accessed 22 Janurary 2012.
[5]  Delacollette C, D’Souza C, Christophel E, Thimasarn K, Abdur R, et al. (2009) Malaria trends and challenges in the Greater Mekong Subregion. Southeast Asian J Trop Med Public Health 40: 674–691.
[6]  Dondorp A, Nosten F, Stepniewska K, Day N, White N (2005) Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366: 717–725.
[7]  Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, et al. (2010) Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376: 1647–1657.
[8]  White NJ (2011) The parasite clearance curve. Malar J 10: 278.
[9]  Sinclair D, Zani B, Donegan S, Olliaro P, Garner P (2009) Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev: CD007483.
[10]  Maiga AW, Fofana B, Sagara I, Dembele D, Dara A, et al. (2012) No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in mali. Am J Trop Med Hyg 87: 23–28.
[11]  Mayxay M, Khanthavong M, Chanthongthip O, Imwong M, Lee SJ, et al. (2012) No evidence for spread of Plasmodium falciparum artemisinin resistance to Savannakhet Province, Southern Laos. Am J Trop Med Hyg 86: 403–408.
[12]  Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F, et al. (2004) In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother 48: 4271–4280.
[13]  Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, et al. (2011) The threat of artemisinin-resistant malaria. N Engl J Med 365: 1073–1075.
[14]  Flegg JA, Guerin PJ, White NJ, Stepniewska K (2011) Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 10: 339.
[15]  World Health Organization (2009) Workshop to review and plan therapeutic efficacy studies to monitor P. falciparum and P. vivax resistance to anti-malarial drugs in the Greater Mekong Sub-region. Available: http://www.whothailand.org/LinkFiles/Mek?ong_Malaria_Programme_Draft_final_report?_mandaly.PDF. Accessed 3 May 3, 2012.
[16]  Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, et al. (2012) Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379: 1960–1966.
[17]  Behrens RH, Carroll B, Hellgren U, Visser LG, Siikamaki H, et al. (2010) The incidence of malaria in travellers to South-East Asia: is local malaria transmission a useful risk indicator? Malar J 9: 266.
[18]  World Health Organization (2000) WHO Expert Committee on Malaria. World Health Organ Tech Rep Ser 892: i–v, 1–74.
[19]  World Health Organization (2009) Methods for surveillance of antimalarial drug effiacy. Available: http://whqlibdoc.who.int/publications/20?09/9789241597531_eng.pdf. Accessed 12 March 2012.
[20]  Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, et al. (1999) Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 93: 369–374.
[21]  Siripoon N, Snounou G, Yamogkul P, Na-Bangchang K, Thaithong S (2002) Cryptic Plasmodium falciparum parasites in clinical P. vivax blood samples from Thailand. Trans R Soc Trop Med Hyg 96: 70–71.
[22]  Hanpithakpong W, Kamanikom B, Dondorp AM, Singhasivanon P, White NJ, et al. (2008) A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 876: 61–68.
[23]  WorldWide Antimalarial Resistance Network. WWARN Parasite Clearance Estimator. Available: http://www.wwarn.org/toolkit/data-manage?ment/parasite-clearance-estimator. Accessed 14 May 2012.
[24]  Starzengruber P, Fuehrer H-P, Swoboda P, Hofecker V, Siedl A, et al. (2010) No evidence that artemisinin-resistant malaria has spread to south Asia (Abstract 473). Am J Trop Med Hyg 83: 142.
[25]  Takala-Harrison S, Clark T, Cummings M, Jacob C, Miotto O, et al. (2011) ARC3: Genome-wide association study of the genetic basis of parasite clearance rate following treatment with artemisinins (Abstract 1047). Am J Trop Med Hyg 85: 315–316.
[26]  Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, et al. (2012) A major genome region underlying artemisinin resistance in malaria. Science 336: 79–82.
[27]  Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, et al. (2000) Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet 39: 255–270.
[28]  Newton P, Suputtamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, Navaratnam V, et al. (2000) Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother 44: 972–977.
[29]  Binh TQ, Ilett KF, Batty KT, Davis TM, Hung NC, et al. (2001) Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. Br J Clin Pharmacol 51: 541–546.
[30]  Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, et al. (2011) Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 52: 612–620.
[31]  Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, et al. (2010) Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. The Lancet infectious diseases 10: 673–681.
[32]  Looareesuwan S, White NJ, Chittamas S, Bunnag D, Harinasuta T (1987) High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet 2: 1052–1055.
[33]  WHO (2012) World Malaria Report (2011) Available: http://www.who.int/malaria/world_malaria?_report_2011/en/.Accessed 16 June 2012.
[34]  World Health Organization. Strategic Framework for Artemisinin Resistance Containment in Myanmar (MARC) (2011–2015) (2011) Available: http://www.whomyanmar.org/LinkFiles/Mala?ria_MARC_framework_April_2011.pdf.Accessed 23 August 2012.
[35]  WorldWide Antimalarial Resistance Network. Tracking resistance to artemisinin collaboration (TRAC) (2012) Available: http://www.wwarn.org/partnerships/projec?ts/trac.Accessed 10 September 10 2012.
[36]  Nyunt MM, Plowe CV (2007) Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance. Clin Pharmacol Ther 82: 601–605.
[37]  Trape JF (2001) The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 64: 12–17.

Full-Text

comments powered by Disqus